BG1461U1 - Compositions of an antiparasitic remedy - Google Patents
Compositions of an antiparasitic remedy Download PDFInfo
- Publication number
- BG1461U1 BG1461U1 BG1949U BG194911U BG1461U1 BG 1461 U1 BG1461 U1 BG 1461U1 BG 1949 U BG1949 U BG 1949U BG 194911 U BG194911 U BG 194911U BG 1461 U1 BG1461 U1 BG 1461U1
- Authority
- BG
- Bulgaria
- Prior art keywords
- drug compositions
- compositions according
- antiparasitic
- antiparasitic drug
- compositions
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 28
- 239000003096 antiparasitic agent Substances 0.000 title claims abstract description 18
- 230000002141 anti-parasite Effects 0.000 title abstract description 7
- QLFZZSKTJWDQOS-YDBLARSUSA-N doramectin Chemical compound O1[C@@H](C)[C@H](O)[C@@H](OC)C[C@@H]1O[C@@H]1[C@@H](OC)C[C@H](O[C@@H]2C(=C/C[C@@H]3C[C@@H](C[C@@]4(O3)C=C[C@H](C)[C@@H](C3CCCCC3)O4)OC(=O)[C@@H]3C=C(C)[C@@H](O)[C@H]4OC\C([C@@]34O)=C/C=C/[C@@H]2C)/C)O[C@H]1C QLFZZSKTJWDQOS-YDBLARSUSA-N 0.000 claims abstract description 8
- 229960003997 doramectin Drugs 0.000 claims abstract description 8
- 239000013543 active substance Substances 0.000 claims abstract description 5
- 239000000126 substance Substances 0.000 claims description 10
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 9
- 239000000314 lubricant Substances 0.000 claims description 9
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 7
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 7
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 7
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 6
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 6
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 6
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 6
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 6
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 5
- 229920002472 Starch Polymers 0.000 claims description 5
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims description 5
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 5
- 229940100445 wheat starch Drugs 0.000 claims description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 4
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 claims description 4
- 239000003085 diluting agent Substances 0.000 claims description 4
- 239000007884 disintegrant Substances 0.000 claims description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 4
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 claims description 3
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims description 3
- 229920000881 Modified starch Polymers 0.000 claims description 3
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims description 3
- 229930003268 Vitamin C Natural products 0.000 claims description 3
- 239000003963 antioxidant agent Substances 0.000 claims description 3
- 235000006708 antioxidants Nutrition 0.000 claims description 3
- 229940093429 polyethylene glycol 6000 Drugs 0.000 claims description 3
- 235000019333 sodium laurylsulphate Nutrition 0.000 claims description 3
- 235000019154 vitamin C Nutrition 0.000 claims description 3
- 239000011718 vitamin C Substances 0.000 claims description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 3
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 claims description 2
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 claims description 2
- 241000287828 Gallus gallus Species 0.000 claims description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 2
- 235000015241 bacon Nutrition 0.000 claims description 2
- 239000011230 binding agent Substances 0.000 claims description 2
- 235000013330 chicken meat Nutrition 0.000 claims description 2
- 239000008119 colloidal silica Substances 0.000 claims description 2
- 229940071676 hydroxypropylcellulose Drugs 0.000 claims description 2
- 229960001021 lactose monohydrate Drugs 0.000 claims description 2
- 239000007788 liquid Substances 0.000 claims description 2
- 210000004185 liver Anatomy 0.000 claims description 2
- 235000019359 magnesium stearate Nutrition 0.000 claims description 2
- 235000013372 meat Nutrition 0.000 claims description 2
- 239000003921 oil Substances 0.000 claims description 2
- 239000000843 powder Substances 0.000 claims description 2
- 235000013580 sausages Nutrition 0.000 claims description 2
- 239000000454 talc Substances 0.000 claims description 2
- 229910052623 talc Inorganic materials 0.000 claims description 2
- 239000001692 EU approved anti-caking agent Substances 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 235000015278 beef Nutrition 0.000 claims 1
- 239000003979 granulating agent Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 abstract description 10
- 238000011321 prophylaxis Methods 0.000 abstract description 2
- 241001465754 Metazoa Species 0.000 description 11
- 206010048282 zoonosis Diseases 0.000 description 10
- 208000035472 Zoonoses Diseases 0.000 description 9
- 238000007865 diluting Methods 0.000 description 6
- 230000002265 prevention Effects 0.000 description 5
- 238000011282 treatment Methods 0.000 description 5
- 241000282472 Canis lupus familiaris Species 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 244000045947 parasite Species 0.000 description 4
- 108010034145 Helminth Proteins Proteins 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 241000002163 Mesapamea fractilinea Species 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 244000000013 helminth Species 0.000 description 3
- 208000003917 Dirofilariasis Diseases 0.000 description 2
- 208000006968 Helminthiasis Diseases 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 208000014837 parasitic helminthiasis infectious disease Diseases 0.000 description 2
- 239000007916 tablet composition Substances 0.000 description 2
- AZSNMRSAGSSBNP-UHFFFAOYSA-N 22,23-dihydroavermectin B1a Natural products C1CC(C)C(C(C)CC)OC21OC(CC=C(C)C(OC1OC(C)C(OC3OC(C)C(O)C(OC)C3)C(OC)C1)C(C)C=CC=C1C3(C(C(=O)O4)C=C(C)C(O)C3OC1)O)CC4C2 AZSNMRSAGSSBNP-UHFFFAOYSA-N 0.000 description 1
- SPBDXSGPUHCETR-JFUDTMANSA-N 8883yp2r6d Chemical compound O1[C@@H](C)[C@H](O)[C@@H](OC)C[C@@H]1O[C@@H]1[C@@H](OC)C[C@H](O[C@@H]2C(=C/C[C@@H]3C[C@@H](C[C@@]4(O[C@@H]([C@@H](C)CC4)C(C)C)O3)OC(=O)[C@@H]3C=C(C)[C@@H](O)[C@H]4OC\C([C@@]34O)=C/C=C/[C@@H]2C)/C)O[C@H]1C.C1C[C@H](C)[C@@H]([C@@H](C)CC)O[C@@]21O[C@H](C\C=C(C)\[C@@H](O[C@@H]1O[C@@H](C)[C@H](O[C@@H]3O[C@@H](C)[C@H](O)[C@@H](OC)C3)[C@@H](OC)C1)[C@@H](C)\C=C\C=C/1[C@]3([C@H](C(=O)O4)C=C(C)[C@@H](O)[C@H]3OC\1)O)C[C@H]4C2 SPBDXSGPUHCETR-JFUDTMANSA-N 0.000 description 1
- 239000005660 Abamectin Substances 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 206010061201 Helminthic infection Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 241000244206 Nematoda Species 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 230000000181 anti-adherent effect Effects 0.000 description 1
- RRZXIRBKKLTSOM-XPNPUAGNSA-N avermectin B1a Chemical compound C1=C[C@H](C)[C@@H]([C@@H](C)CC)O[C@]11O[C@H](C\C=C(C)\[C@@H](O[C@@H]2O[C@@H](C)[C@H](O[C@@H]3O[C@@H](C)[C@H](O)[C@@H](OC)C3)[C@@H](OC)C2)[C@@H](C)\C=C\C=C/2[C@]3([C@H](C(=O)O4)C=C(C)[C@@H](O)[C@H]3OC\2)O)C[C@H]4C1 RRZXIRBKKLTSOM-XPNPUAGNSA-N 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 229960002418 ivermectin Drugs 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000002574 microfilaricid Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 231100000759 toxicological effect Toxicity 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Област на техникатаTechnical field
Полезният модел се отнася до състави на противопаразитно лекарствено средство за борба с хелминтозни зоонози, които намират приложение във ветеринарната медицина.The utility model relates to compositions of an antiparasitic drug for the control of helminth zoonoses, which are used in veterinary medicine.
Предшестващо състояние на техникатаBACKGROUND OF THE INVENTION
Известно е, че болестите зоонози - общи за животните и човека, придобиват все по-голяма актуалност. Това е породено от засилването на контактите на човека с домашните и с живеещите на свобода животни поради стопански, любителски и други съображения. В световната здравна наука и практика е прието с термина “зооноза” да се означават болести, които засягат и животните и човека. Важността на въпроса за зоонозите се корени в особено голямото им социално здравно значение. Въпросът за ролята на животните при зоонозите не се свежда единствено до съществуващата етиологична общност на причиняваните заболявалия. Главното в случая е решаващото участие на животните при предаването и поддържането на зоонозите. Те са източник на причинителя на инфекцията за хората и резервоар на заразата. Директива 2003/99/ЕО на Европейския парламент гласи, че опазването здравето на човека от болести и инфекции, които се предават директно или индиректно от животните на човека (зоонози) е от първостепенно значение. Зоонозите, предавани чрез източници, различни от храната, по-специално чрез популациите на живи животни и домашни любимци, също пораждат сериозно безпокойство.Zoonotic diseases, common to animals and humans, are known to become increasingly relevant. This is due to the intensification of human contact with domestic and free-living animals for economic, recreational and other reasons. In the world of health science and practice it is accepted by the term "zoonosis" to mean diseases that affect both animals and humans. The importance of the issue of zoonoses is rooted in their particularly high social health importance. The question of the role of animals in zoonoses is not limited to the existing etiological community of the diseases caused. The key here is the crucial involvement of animals in the transmission and maintenance of zoonoses. They are the source of the infectious agent for humans and the reservoir of infection. Directive 2003/99 / EC of the European Parliament states that the protection of human health from diseases and infections transmitted directly or indirectly by human animals (zoonoses) is of paramount importance. Zoonoses transmitted through sources other than food, in particular through populations of live animals and pets, are also of major concern.
Зоонозата дирофилариоза е позната по целия свят, с изключение на арктическите и северните умерени области. Известна е още като сърдечна нематодна болест по кучетата - caninae heartworm disease. В световен мащаб, числеността на кучетата, съставлява над 20% от числеността на населението, като тенденцията е тя да се увеличава.Zoonotic heartworm is known worldwide, except in the Arctic and northern temperate regions. It is also known as canine nematode disease in dogs - caninae heartworm disease. Worldwide, dog numbers make up over 20% of the population, with the tendency to increase.
Известно е използването на различни състави на противопаразитни лекарствени средства под формата на таблети, гранули, spot on и др. за профилактика на дирофилариозата при кучета (US 3856971, US 7064108, US 6469067,It is known to use various formulations of antiparasitic drugs in the form of tablets, granules, spot on and the like. for the prevention of dirofilariosis in dogs (US 3856971, US 7064108, US 6469067,
ЕР 1522219, US 6426333).EP 1522219, US 6426333).
Известни са противопаразитни лекарствени средства като моновалентни таблетни форми, които съдържат авермектин или ивермектин. Основен проблем при тяхното прилагане са констатираните странични ефекти при някои породи кучета.Antiparasitic drugs are known, such as monovalent tablet formulations containing avermectin or ivermectin. A major problem with their application is the observed side effects in some dog breeds.
Известни са поливалентни (съдържащи две и повече активни вещества) таблетни форми, в които освен активно вещество срещу дирофилариите, са включени една или повече антипаразитни субстанции срещу други видове паразити. При профилактика на дирофилариоза те трябва да се прилагат ежемесечно, докато срещу другите паразити е необходимо третиране през два или три месеца. Ежемесечното третиране с този вид таблети натоварва излишно организма на животните с антипаразитни субстанции, предназначени за контрол на другите паразити, като едновременно с това предизвикват устойчивост (резистентност) на паразитите към тях, което води до намаляване на тяхната ефективност и оскъпяване на профилактиката.Polyvalent (containing two or more active substances) tablet formulations are known in which one or more antiparasitic substances against other types of parasites are included in addition to the active substance against the heartworm. For the prevention of heartworm disease, they should be administered monthly, while treatment with other parasites requires treatment every two or three months. Monthly treatment with this type of tablet unnecessarily burdens the animal body with antiparasitic substances intended to control other parasites, while at the same time causing resistance (resistance) of the parasites to them, which leads to a decrease in their effectiveness and a high cost of prevention.
Известни са гранулирани противопаразитни форми, които се прилагат с водата за пиене или храната на животните. Недостатък при тях е, невъзможността да се контролира количеството на консумацията. Възможно е да не се изконсумира определеното количество и по този начин да не се приеме цялата доза от продукта, което води до слаба ефективност на тези форми.Granular antiparasitic forms are known to be administered with drinking water or animal feed. The downside to them is the inability to control the amount of consumption. It is possible not to consume the specified amount and thus not to take the entire dose of the product, which leads to poor efficacy of these forms.
Известно е използването на резорбируеми форми, чрез накапване на едно място на гърба (spot on). Проблемите се изразяват във възникване на кожно-алергични реакции на мястото на прилагане, изразяващи се в силен сърбеж и зачервяване; повторно третиране, в случаите на често излагане тялото на вода, което оскъпява третирането; повишен риск от токсикологични реакции, в резултат от попадане на продукта върху кожата, очите и видимите лигавици на възрастни или деца, които са в контакт с третирани животни.The use of absorbable shapes is known by spot spot deposition. Problems are expressed in the occurrence of skin-allergic reactions at the site of application, resulting in severe itching and redness; re-treatment, in cases of frequent exposure to the body of water, which increases the cost of treatment; increased risk of toxicological effects resulting from the product falling on the skin, eyes and visible mucous membranes of adults or children in contact with treated animals.
Техническа същност на полезния моделThe technical nature of the utility model
Същност на полезния модел са състави на противопаразитно лекарствено средство за борба с хелминтозни зоонози, предназначени за ветеринарната медицина.The essence of the utility model are formulations of an antiparasitic drug for the control of helminth zoonoses intended for veterinary medicine.
1461 Ul1461 Ul
Така полученото лекарствено средство дава ново решение за контрол на дирофилариозата при животни и преодоляване на недостатъците, посочени в състоянието на техниката, които съществуват при традиционната профилактика на хелминтозите при животните във ветеринарната медицина. Получените състави, съгласно полезния модел включват в тегл. %: активно вещество дорамектин от 0,005 до 25,0; разреждащи вещества (дилуенти) от 80,0 до 90,0 (лактоза монохидрат, пшенично нишесте и микрокристална целулоза); свързващи (гранулиращи) вещества от 1,0 до 10,0 (хидроксипропилцелулоза, прежелатинизирано нишесте и поливинилпиролидон); антиоксиданти от 0,01 до 3,0 (бутил хидрокситолуол, бутил хидроксианизол, лимонена киселина и витамин С); разпадащи вещества от 0,1 до 5,0 (пшенично нишесте, хидроксипропилцелулоза, микрокристална целулоза, поливинилпиролидон, натриев лаурилсулфат, полиетиленгликол 6000); смазващи, противослепващи и хлъзгащи вещества от 0,1 до 0,5 (магнезиев стеарат, талк, колоидален силициев диоксид); ароматизиращи вещества от 0,001 до 1,0 (от естествен или синтетичен произход, под формата на прах или течност, разтворими във вода, етанол или масло с аромат на шунка, месо, бекон, пиле, телешко, черен дроб и наденица).The drug thus obtained provides a new solution for the control of animal heartworm and to overcome the deficiencies identified in the prior art for the traditional prevention of helminthiasis in animals in veterinary medicine. The formulations obtained according to the utility model are included in wt. %: doramectin active substance from 0.005 to 25.0; diluents (diluents) from 80.0 to 90.0 (lactose monohydrate, wheat starch and microcrystalline cellulose); binders from 1.0 to 10.0 (hydroxypropylcellulose, pregelatinized starch and polyvinylpyrrolidone); antioxidants from 0.01 to 3.0 (butyl hydroxytoluene, butyl hydroxyanisole, citric acid and vitamin C); disintegrants from 0.1 to 5.0 (wheat starch, hydroxypropyl cellulose, microcrystalline cellulose, polyvinylpyrrolidone, sodium lauryl sulfate, polyethylene glycol 6000); lubricants, anti-adhesives and glidants from 0.1 to 0.5 (magnesium stearate, talc, colloidal silica); flavoring substances from 0,001 to 1,0 (of natural or synthetic origin, in the form of powder or liquid, soluble in water, ethanol or oil, flavored with ham, meat, bacon, chicken, veal, liver and sausage).
Съставите са стабилни и се прилагат под 5 формата на твърдо дозирано лекарствено средство.The compositions are stable and are administered in the form of a solid dosage form.
Примери за изпълнение на полезния моделExamples of implementation of the utility model
Следващите примери илюстрират ефекта от изобретението, но не бива да се счита, че го ограничават по какъвто и да е начин.The following examples illustrate the effect of the invention, but should not be construed to limit it in any way.
Съставите на лекарственото средство за профилактика на хелминтозни зоонози са описани в примери от 1 до 5.The compositions of the drug for the prevention of helminth zoonoses are described in Examples 1 to 5.
Последователността на технологичните операции за получаване на противопаразитното лекарствено средство е следната:The sequence of technological operations for the preparation of the anti-parasite drug is as follows:
1. Пресяване, претегляне и смесване на разреждащите вещества.1. Sieving, weighing and mixing of diluting substances.
2. Изготвяне на гранулиращи разтвори.2. Preparation of granulating solutions.
3. Сместа от т. 1 се гранулира и изсушава.3. The mixture of item 1 is granulated and dried.
4. Към сместа от т. 3 се добавят смазващите и разпадащи вещества.4. Lubricants and disintegrants are added to the mixture of item 3.
5. Сместа от т. 4 се таблетира.5. The mixture of item 4 is tableted.
В зависимост от вида на животните и тежестта на хелминтозата се подхожда индивидуално и се прилага, един от изброените състави.Depending on the type of animal and the severity of the helminthosis, one of the listed compositions is individually administered and administered.
ПРИМЕР 1:EXAMPLE 1:
ПРИМЕР 2:EXAMPLE 2:
Ароматизиращи вещества i 0,001- 1,0Flavorings i 0,001-1,0
Разреждащи веществаDiluting substances
80,0 - 90,080.0 - 90.0
ПРИМЕР 5:EXAMPLE 5:
Резултатите от проведените in vitro и in vivo изследвания с описаните състави в примерите от 1 до 5, дават основание да бъде направено заключението, че използваните състави проявяват ясно изразена микрофиларицидна активност.The results of the in vitro and in vivo studies performed with the described compositions in Examples 1 to 5 suggest that the compositions used exhibit a distinct microfilaricidal activity.
Прилагането на това лекарствено средство във ветеринарната медицина дава ново решение на основните проблеми, които съществуват при традиционната профилактика на хелминтозите, представляващи зоонози.The use of this drug in veterinary medicine provides a new solution to the major problems that exist in the traditional prophylaxis of zoonotic helminthoses.
Claims (8)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| BG1949U BG1461U1 (en) | 2011-03-18 | 2011-03-18 | Compositions of an antiparasitic remedy |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| BG1949U BG1461U1 (en) | 2011-03-18 | 2011-03-18 | Compositions of an antiparasitic remedy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BG1461U1 true BG1461U1 (en) | 2011-07-29 |
Family
ID=45877083
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BG1949U BG1461U1 (en) | 2011-03-18 | 2011-03-18 | Compositions of an antiparasitic remedy |
Country Status (1)
| Country | Link |
|---|---|
| BG (1) | BG1461U1 (en) |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3856971A (en) * | 1971-07-20 | 1974-12-24 | E Friedheim | Method of combating filariasis in dogs |
| US6426633B1 (en) * | 1999-06-18 | 2002-07-30 | Danfoss Drives A/S | Method for monitoring a rotational angle sensor on an electrical machine |
| US6469067B1 (en) * | 1999-11-25 | 2002-10-22 | Novartis Ag | Combinations |
| EP1522219A1 (en) * | 1998-11-19 | 2005-04-13 | Pfizer Limited | Antiparasitic formulations |
| US7064108B2 (en) * | 2002-02-08 | 2006-06-20 | Merck & Co., Inc. | Topical ivermectin composition |
-
2011
- 2011-03-18 BG BG1949U patent/BG1461U1/en unknown
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3856971A (en) * | 1971-07-20 | 1974-12-24 | E Friedheim | Method of combating filariasis in dogs |
| EP1522219A1 (en) * | 1998-11-19 | 2005-04-13 | Pfizer Limited | Antiparasitic formulations |
| US6426633B1 (en) * | 1999-06-18 | 2002-07-30 | Danfoss Drives A/S | Method for monitoring a rotational angle sensor on an electrical machine |
| US6469067B1 (en) * | 1999-11-25 | 2002-10-22 | Novartis Ag | Combinations |
| US7064108B2 (en) * | 2002-02-08 | 2006-06-20 | Merck & Co., Inc. | Topical ivermectin composition |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DOP2010000166A (en) | AMINOBENZAMIDE DERIVATIVES AS USEFUL AGENTS FOR THE CONTROL OF PARASITES OF ANIMALS | |
| US20050032718A1 (en) | Anthelmintic formulations | |
| Melaku et al. | Drugs and drug resistance in African animal trypanosomosis: a review | |
| JP2019167358A (en) | Composition for pest controlling microsporidia of seafood, and pest controlling method of microsporidia of seafood | |
| CN110721167A (en) | A kind of compound deworming flavor tablet composition for pets and preparation method thereof | |
| CN101450055A (en) | Soluble powder for treating livestock and poultry bacterial infection and parasitic disease | |
| US7582612B2 (en) | Multi-action anthelmintic formulations | |
| TW201221066A (en) | Lauric acid distillate for animal feed | |
| Kawano et al. | Antiparasitic effect of in-feed inhibitors of folic acid synthesis and dihydrofolate reductase against ciliate Cryptocaryon irritans infection in the red sea bream Pagrus major and against ciliate Ichthyophthirius multifiliis infection in black pop-eyed goldfish Carassius auratus | |
| CN101011408A (en) | Animal-used compound preparation for treating parasitic disease in or out of livestock and fowl body and preparation method thereof | |
| CN109999027B (en) | Use of melatonin | |
| BG1461U1 (en) | Compositions of an antiparasitic remedy | |
| US9040586B2 (en) | Veterinary compositions for controlling ecto- and endoparasites in bovines, use of these compositions, use of IGR substances associated with microminerals, method for controlling ecto- and endoparasites in bovines and kit | |
| CN101468025A (en) | Soluble powder for preventing and treating colibacillosis of fowl | |
| US20230114459A1 (en) | Composition for Use in the Prophylaxis and Treatment of Viral Infections of the Asfarviridae Family | |
| RU2412698C1 (en) | Method of treating helminthiases in ruminants and medicinal agent for implementation thereof | |
| CN104739857A (en) | Pharmaceutical composition for treating dermatomycosis of young rabbits | |
| CN103690546B (en) | A kind of cat is with prevention and treat oral disnitegration tablet of toxoplasmosis and preparation method thereof | |
| US12042512B2 (en) | Method and use of compositions comprising lignosulfonate and substantially free of elemental sulphur for pathogenic attenuation | |
| RU2511304C2 (en) | Method of increasing adaptive status of bee family | |
| CA2794481A1 (en) | Carvacrol and/or thymol or composition thereof for preventing of infection or infestation of an ectoparasitic copepod in fish | |
| Sutili et al. | Clove Oil, eugenol effective anesthetics for silver catfish, other Brazilian species | |
| CN101268810B (en) | Composite prebiotics feed additive | |
| AU2006324315A1 (en) | Veterinarian composition comprising an organic salt of levamisole in combination with at least one avermectine and/or milbemycine | |
| CN103751199A (en) | Composite pesticide and preparation method thereof |